BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants with moderate to severe chronic plaque psoriasis.
Epistemonikos ID: 0b6e84f2bb308555cd6cf3494040ffd6e864d70b
First added on: Feb 15, 2022